Virtual Reality Exposure for Socially Anxious Adolescents (VIRTUS)

April 17, 2024 updated by: Dirk Hermans, KU Leuven

Virtual Reality Exposure for Socially Anxious Adolescents: A Randomized Controlled Trial (RCT)

Overall in this project, the primary goal is to evaluate the efficacy of virtual reality exposure (VRE) for adolescents with elevated social anxiety using a three-arm randomized controlled trial: (1) virtual reality exposure (VRE); (2) in vivo exposure (IVE); and (3) waitlist (WL) - the control condition.

It is predicted that both VRE and IVE will be more successful in decreasing social anxiety symptoms than the WL condition at post-assessment and that VRE will be as effective as in vivo in reducing social anxiety symptoms. Furthermore, it is expected that there will be no difference between the two active conditions in the long term (at 3- months & 6-months follow up). Similar results are expected in the secondary outcome measures, intended to capture the participants' general well-being.

Moreover, the study has the following (secondary) objectives:

  • To elucidate potential working mechanisms of VRE and IVE
  • To identify predictors of adolescents' response to VRE and IVE
  • To assess to what extent adolescents accept VRE and IVE and how they experience it

Study Overview

Detailed Description

This study is going to be a single-blinded, randomized controlled trial (RCT) with three arms: VRE, IVE, and a WL condition. It will follow a mixed-subjects design with condition as a between factor and measurement time-points as a within factor. Due to the study's goal to unravel the effects of VRE, the focus of the intervention will be on exposure in both active conditions (without explicitly including other treatment components like cognitive restructuring). The intervention will take place either at participants' schools or at KU Leuven (i.e., PraxisP - the outpatient treatment facility of the Faculty of Psychology and Educational Sciences, PSI - Psychological Institute) depending on the participants' preference and availability. In case this is not possible, neighboring healthcare practices will be explored as an alternative option. In any case, the training will be held in a separate, private room where the privacy of the participant can be guaranteed. Each active condition will comprise of 7 training sessions in total approximately 90 minutes each.

At pre-assessment, all primary and secondary outcome measures and most of the predictors will be assessed approximately one week prior to the first session. The outcome measures will be re-assessed during the post-assessment (one week after the last session) and the follow up assessments (3-months & 6-months following the post assessment). During the training sessions, measurements of the mechanisms, remaining predictors, and participant feedback will be acquired and at mid-assessment an additional measurement of the primary outcome measures (e.g., social anxiety measures) will be obtained. Moreover, a brief social anxiety measure will also be conducted on a weekly basis to record symptom-related changes from session to session. Following the training, a qualitative interview will be conducted. This semi-structured interview will be conducted in a convenience sample of participants from both active conditions (e.g., 10-16 participants per condition due to pragmatic considerations and based on general recommendations as to when theoretical data saturation can be reached) to investigate VRE's acceptability and to compare it to IVE. To decrease demand effects, the (online) interview will be conducted by an independent interviewer (e.g., not the therapist) and will be audio-taped so that the interviewer can focus solely on the interaction.

Moreover, in line with good clinical practice and individualized treatment, the specific nature and content of the exposure exercises will be determined for each participant individually by presenting them with an extensive list of the possible exercises (e.g., ordering food in a restaurant, asking a question in class, engaging in a group conversation) in combination with a functional analysis. To ensure that the active conditions are comparable, the IVE condition will be matched to the VRE condition in terms of exposure duration and homework assignments will not be actively encouraged in both conditions. The crucial difference between the two active conditions is that in the IVE condition the exercises take place in real life, whereas in VRE the exercises take place in virtual reality. For the WL condition, the (primary and secondary) outcome measures will be administered before, during, and after the given waiting period (i.e., duration of training sessions) at the same instances as with the active conditions. After that time, participants in the WL condition will have the opportunity to be randomized into IVE and VRE.

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Leuven, Belgium, 3000 Leuven
        • Recruiting
        • Psychological Institute (PSI) of KU Leuven
        • Contact:
        • Contact:
        • Principal Investigator:
          • Dirk Hermans, PhD
        • Sub-Investigator:
          • Iris Engelhard, PhD
        • Sub-Investigator:
          • Katharina Meyerbröker, PhD
        • Sub-Investigator:
          • Sara Scheveneels, PhD
        • Sub-Investigator:
          • Jella De Lee, MSc
        • Sub-Investigator:
          • Elizabeth S Uduwa-vidanalage, MSc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion:

  • Elevated levels of social anxiety (as per the Social Phobia Inventory; ≥ 19)
  • Fluent in Dutch
  • 12-16 years old

Exclusion

  • Severe social anxiety disorder
  • Severe depression
  • Psychotic symptoms
  • Severe suicidal thoughts and / or severe self-harm
  • Severe substance use
  • Benzodiazepine use and / or a change of psychoactive medication usage (dose, type)
  • Autism spectrum disorder (ASD) diagnosis
  • Current ongoing psychological treatment (or waitlisted) for anxiety disorders and or depression
  • Other urgent psychopathologies and/or mismatch between participants' clinical presentation and the offered training
  • Exposure therapy for social anxiety disorder in the past 2 years
  • Another person from the same household is participating in the study
  • Eligible for VR as per the following criteria:
  • History of extreme/severe motion sickness (e.g., car sick, sea-sick) and / or experiencing extreme/severe symptoms of motion sickness during 3D movies
  • Stereoscopic vision problem or a balance problem that would hinder the VR experience;
  • History of seizures, seizure disorder or epilepsy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Virtual reality exposure (VRE)
Participants in the VRE condition will be exposed to various VR-based one-on-one and group social interactions which tend to elicit anxiety. That is, commonly feared situations and events (e.g., raising your hand in class, saying no to a friend, ordering food at a restaurant, calling a classmate to invite them to hang out) will be recreated in the virtual environments. Exercises will be tailored to the participant and provided by clinical psychologists under supervision of experienced CBT therapists (and supervisors). To deliver VRE we will utilize a dynamic and interactive VR-software called 'Social Worlds' developed by CleVR. It has various functions and capabilities (e.g., role-playing, walking around, change of perspective, alteration of dialogue style, number of avatars present in the virtual environment) which enables individualized exposure.
Exposure in virtual reality involves the confrontation with fear-evoking situations which are generated by a computer using VR technology.
Active Comparator: In vivo exposure (IVE)
Similarly to VRE, participants in the IVE condition will be exposed to various one-on-one and group social interactions which tend to elicit anxiety, but they will do so in real-life. The exposure exercises here also will be determined in consultation with the participant. Depending on the given exposure exercise, exposure will either take place at the training location or in its neighborhood (e.g., nearby supermarkets, subway stations, cafes, buses). Exercises will be tailored to the participant and provided by clinical psychologists under supervision of experienced CBT therapists (and supervisors). Importantly, participants will undergo the same amount of exposure sessions as in the VRE condition (to keep exposure time constant).
Exposure in vivo involves the confrontation with fear-evoking situations in real life.
No Intervention: Waitlist
The participants in the WL condition will complete the assessments at the same time points as in the active conditions but will not receive any of the sessions until post-assessment has been completed. Then they will be randomly assigned to one of the two active conditions (VRE or IVE).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Brief version of the Social Phobia and Anxiety Inventory (SPAI-18)
Time Frame: Pre-assessment, after 4 weeks, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)* *Due to practical reasons (e.g., school vacation) the exact number of weeks may change. This applies for all the timepoints except pre-assessment.
General measure of social anxiety
Pre-assessment, after 4 weeks, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)* *Due to practical reasons (e.g., school vacation) the exact number of weeks may change. This applies for all the timepoints except pre-assessment.
Liebowitz Social Anxiety Scale for Children and Adolescents (LSAS-CA) - Avoidance subscale
Time Frame: Pre-assessment, after 4 weeks, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
Avoidance measure of social anxiety
Pre-assessment, after 4 weeks, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
Behavioral assessment task (BAT) - Peak anxiety
Time Frame: Pre-assessment, after 8 weeks*
Subjective units of distress (SUD) measured on a visual analogue scale (VAS); administered immediately after the BAT
Pre-assessment, after 8 weeks*

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Brief Resilience Scale (BRS)
Time Frame: Pre-assessment, after 4 weeks, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
General measure of resilience
Pre-assessment, after 4 weeks, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
Multidimensional Adolescent Functioning Scale (MAFS) - Peer and General functioning subscales
Time Frame: Pre-assessment, after 4 weeks, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
General measure of psychosocial functioning
Pre-assessment, after 4 weeks, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
Revised Children's Anxiety and Depression Scale (RCADS)
Time Frame: Pre-assessment, after 4 weeks, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
General measure of depression and anxiety + Predictor
Pre-assessment, after 4 weeks, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
Self-Efficacy Questionnaire for Children (SEQ-C) - Social efficacy subscale
Time Frame: Pre-assessment, after 4 weeks, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
General measure of social self efficacy and mechanism
Pre-assessment, after 4 weeks, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
Social Phobia Weekly Summary Scale (SPWSS)
Time Frame: Pre-assessment, every training week (up to 7 weeks after pre-assessment), after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
Weekly measure of social anxiety
Pre-assessment, every training week (up to 7 weeks after pre-assessment), after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
Liebowitz Social Anxiety Scale for Children and Adolescents (LSAS-CA) - Fear subscale
Time Frame: Pre-assessment, after 4 weeks, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
Secondary measure of fear regarding specific social situations
Pre-assessment, after 4 weeks, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
Adolescent Social Cognitions Questionnaire (ASCQ)
Time Frame: Pre-assessment, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
Secondary outcome and mechanism & predictor
Pre-assessment, after 8 weeks, follow-up(after 20 weeks), follow up(after 32 weeks)*
Behavioral assessment task (BAT) - Anticipatory anxiety
Time Frame: Pre-assessment, after 8 weeks*
Subjective units of distress (SUD) measured on a visual analogue scale (VAS) immediately before the BAT
Pre-assessment, after 8 weeks*
Behavioral assessment task (BAT) - Physiological assessment
Time Frame: Pre-assessment, after 8 weeks*
Mean heart rate measured during the BAT
Pre-assessment, after 8 weeks*
Behavioral assessment task (BAT) - Physiological assessment
Time Frame: Pre-assessment, after 8 weeks*
Heart-rate variability measured during the BAT
Pre-assessment, after 8 weeks*
Behavioral assessment task (BAT) - Physiological assessment
Time Frame: Pre-assessment, after 8 weeks*
Skin conductance response measured during the BAT
Pre-assessment, after 8 weeks*
Behavioral assessment task (BAT) - Task duration
Time Frame: Pre-assessment, after 8 weeks*
Duration of task in seconds
Pre-assessment, after 8 weeks*
Behavioral assessment task (BAT) - Confederate rating
Time Frame: Pre-assessment, after 8 weeks*
During the BAT, the confederate will rate the participants' social anxiety and performance on a 5-point Likert scale
Pre-assessment, after 8 weeks*

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Behavioral inhibition system / behavioral activation system scale (BIS/BAS)
Time Frame: Pre-assessment
Predictor
Pre-assessment
Experiences in Close Relationship Scale - Relationship Structures (ECR-RS)
Time Frame: Pre-assessment
Predictor
Pre-assessment
Immersive Tendency Questionnaire (ITQ) - Factor Involvement
Time Frame: Pre-assessment
Predictor
Pre-assessment
Unified Theory of Acceptance and Use of Technology (UTAUT-A) - Attitudes subscale
Time Frame: Pre-assessment
Predictor
Pre-assessment
Unified Theory of Acceptance and Use of Technology (UTAUT-EC) - Expectancy subscale
Time Frame: Pre-assessment
Predictor
Pre-assessment
VR experience, motivation, need for connection/relatedness, openness to experiences
Time Frame: Pre-assessment
Predictors - Each construct mentioned above will be measured on a single VAS
Pre-assessment
Preference for treatment question
Time Frame: Pre-assessment
Predictor measured as a binary outcome
Pre-assessment
Credibility and Expectancy Questionnaire (CEQ)
Time Frame: 1 week after pre-assessment*
Predictor
1 week after pre-assessment*
Working Alliance Inventory-Short Form (WAI-S)
Time Frame: 2 and 6 weeks after pre-assessment*
Predictor
2 and 6 weeks after pre-assessment*
Exposure log questions - expectancy violation & expectancy change
Time Frame: Weekly training sessions (up to 7 weeks after pre-assessment)*

Mechanism - Measures related to threat expectancies (e.g., likelihood of threat expectancy, how bad it would be if it occurred) and threat occurrence (e.g., extent to which it occurred, surprise, relief, adjusted threat expectancy).

These variables will be collected prior to and after the exposure exercises and will be primarily assessed using visual analogue scales (VASs).

Weekly training sessions (up to 7 weeks after pre-assessment)*
Exposure log open-ended questions - expectancy violation & expectancy change
Time Frame: Weekly training sessions (up to 7 weeks after pre-assessment)*
Mechanism - open ended questions (e.g., what they learned, how they know that their threat expectancy did not occur) will also be asked to provide further context and to provide more insights into the participants' responses.
Weekly training sessions (up to 7 weeks after pre-assessment)*
Exposure log questions - within- & between- session habituation
Time Frame: Weekly training sessions (up to 7 weeks after pre-assessment)*

Mechanism - Subjective units of distress prior (anticipatory fear/anxiety) and after the exposure exercises (end fear/anxiety & peak fear/anxiety).

They will be measured using visual analogue scales (VASs)

Weekly training sessions (up to 7 weeks after pre-assessment)*
Exposure log question- Self-efficacy
Time Frame: Weekly training sessions (up to 7 weeks after pre-assessment)*
Mechanism - Visual analogue scale (VAS) measuring self-efficacy regarding handling social situations
Weekly training sessions (up to 7 weeks after pre-assessment)*
Exposure log question - Presence
Time Frame: Weekly training sessions (up to 7 weeks after pre-assessment)*
Mechanism - Only in the VRE condition a measure of presence (e.g., measuring how present they feel in the VR environment) will be collected for each exposure exercise.
Weekly training sessions (up to 7 weeks after pre-assessment)*
Exposure log questions - Participant feedback
Time Frame: Weekly training sessions (up to 7 weeks after pre-assessment)*
During each training session, visual analogue scales (VASs) will be administered to measure exercise difficulty, exercise usefulness/relevance, use of safety behaviors, and motivation to participate in the next session
Weekly training sessions (up to 7 weeks after pre-assessment)*
Acceptability interview
Time Frame: Between post-assessment and first follow-up (between 8 and 20 weeks after pre-assessment)
A semi-structured interview will be conducted in a convenience sample of participants from both active conditions (e.g., 10 participants per condition) to investigate VRE's acceptability and to compare it to IVE.
Between post-assessment and first follow-up (between 8 and 20 weeks after pre-assessment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Dirk Hermans, PhD, KU Leuven

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 27, 2024

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

June 1, 2026

Study Registration Dates

First Submitted

April 2, 2024

First Submitted That Met QC Criteria

April 17, 2024

First Posted (Actual)

April 23, 2024

Study Record Updates

Last Update Posted (Actual)

April 23, 2024

Last Update Submitted That Met QC Criteria

April 17, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There are no concrete plans to upload individual participant data on to any platforms. However, if other researchers request for the pseudo-anonymized data, then an agreement can be made to share the data.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Social Anxiety

Clinical Trials on (Virtual reality) exposure

Subscribe